ELISA/assay

Sheep Platelet Derived Growth Factor ELISA Kit

MBS742879

48-Strip-Wells

470 USD

ELISA Kit

Sheep Platelet Derived Growth Factor ELISA Kit

Platelet Derived Growth Factor

platelet-derived growth factor; Platelet-derived growth factor subunit B; platelet-derived growth factor subunit B; becaplermin; PDGF, B chain; PDGF subunit B; proto-oncogene c-Sis; platelet-derived growth factor 2; platelet-derived growth factor B chain; platelet-derived growth factor, beta polypeptide (oncogene SIS); platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog); platelet-derived growth factor beta polypeptide; PDGF-2; Platelet-derived growth factor B chain; Platelet-derived growth factor beta polypeptide; Proto-oncogene c-Sis; INN: Becaplermin

PDGF

PDGFB; PDGFB; SIS; SSV; IBGC5; PDGF2; c-sis; PDGF-2; PDGF2; SIS; PDGF subunit B

PDGFB_HUMAN

Sheep

This assay has high sensitivity and excellent specificity for detection of PDGF. No significant cross-reactivity or interference between PDGF and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between PDGF and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, cell culture supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: The sensitivity in this assay is1.0pg/mL.

Intended Uses: This PDGF ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Sheep PDGF. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Principle of the Assay: PDGF ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-PDGF antibody and an PDGF-HRP conjugate. The assay sample and buffer are incubated together with PDGF-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the PDGF concentration since PDGF from samples and PDGF-HRP conjugate compete for the anti-PDGF antibody binding site. Since the number of sites is limited, as more sites are occupied by PDGF from the sample, fewer sites are left to bind PDGF-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The PDGF concentration in each sample is interpolated from this standard curve.

338209

AAA60552.1

25,502 Da

Adaptive Immune System Pathway (366160); Angiogenesis Pathway (198772); Constitutive PI3K/AKT Signaling In Cancer Pathway (685535); Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); DAP12 Interactions Pathway (685549); DAP12 Signaling Pathway (685550); Disease Pathway (530764); Downstream Signal Transduction Pathway (106385); Downstream Signaling Events Of B Cell Receptor (BCR) Pathway (576250)

The protein encoded by this gene is a member of the platelet-derived growth factor family. The four members of this family are mitogenic factors for cells of mesenchymal origin and are characterized by a motif of eight cysteines. This gene product can exist either as a homodimer (PDGF-BB) or as a heterodimer with the platelet-derived growth factor alpha polypeptide (PDGF-AB), where the dimers are connected by disulfide bonds. Mutations in this gene are associated with meningioma. Reciprocal translocations between chromosomes 22 and 17, at sites where this gene and that for collagen type 1, alpha 1 are located, are associated with a particular type of skin tumor called dermatofibrosarcoma protuberans resulting from unregulated expression of growth factor. Two alternatively spliced transcript variants encoding different isoforms have been identified for this gene. [provided by RefSeq, Feb 2013]

PDGFB: Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. Potent mitogen for cells of mesenchymal origin. Required for normal proliferation and recruitment of pericytes and vascular smooth muscle cells in the central nervous system, skin, lung, heart and placenta. Required for normal blood vessel development, and for normal development of kidney glomeruli. Plays an important role in wound healing. Signaling is modulated by the formation of heterodimers with PDGFA. A chromosomal aberration involving PDGFB is found in dermatofibrosarcoma protuberans. Translocation t(17;22)(q22;q13) with PDGFB. Belongs to the PDGF/VEGF growth factor family. Protein type: Motility/polarity/chemotaxis; Secreted, signal peptide; Secreted; Oncoprotein. Chromosomal Location of Human Ortholog: 22q13.1. Cellular Component: Golgi membrane; extracellular space; cell surface; endoplasmic reticulum lumen; basolateral plasma membrane; cytoplasm; extracellular region. Molecular Function: collagen binding; identical protein binding; protein binding; protein homodimerization activity; growth factor activity; protein heterodimerization activity; platelet-derived growth factor binding; platelet-derived growth factor receptor binding; superoxide-generating NADPH oxidase activator activity; chemoattractant activity. Biological Process: extracellular matrix organization and biogenesis; positive regulation of cyclin-dependent protein kinase activity; nerve growth factor receptor signaling pathway; positive regulation of transcription, DNA-dependent; heart development; positive regulation of fibroblast growth factor receptor signaling pathway; cell projection biogenesis; protein amino acid phosphorylation; monocyte chemotaxis; positive regulation of MAP kinase activity; positive regulation of fibroblast proliferation; positive chemotaxis; transforming growth factor beta receptor signaling pathway; positive regulation of mitotic cell cycle, embryonic; cell growth; substrate-bound cell migration; response to drug; platelet activation; fibroblast growth factor receptor signaling pathway; positive regulation of mitosis; positive regulation of chemotaxis; activation of protein kinase B; positive regulation of blood vessel endothelial cell migration; positive regulation of protein amino acid autophosphorylation; positive regulation of phosphoinositide 3-kinase cascade; positive regulation of peptidyl-tyrosine phosphorylation; activation of protein kinase activity; blood vessel morphogenesis; positive regulation of endothelial cell proliferation; actin cytoskeleton organization and biogenesis; negative regulation of transcription, DNA-dependent; embryonic placenta development; peptidyl-tyrosine phosphorylation; positive regulation of smooth muscle cell proliferation; platelet-derived growth factor receptor signaling pathway; positive regulation of smooth muscle cell migration; response to estradiol stimulus; response to insulin stimulus; platelet degranulation; positive regulation of MAPKKK cascade; positive regulation of glomerular filtration; positive regulation of cell proliferation; response to wounding; hemopoiesis; DNA replication; negative regulation of cell migration; epidermal growth factor receptor signaling pathway; phosphoinositide-mediated signaling; negative regulation of phosphatidylinositol biosynthetic process; positive regulation of phosphoinositide 3-kinase activity; peptidyl-serine phosphorylation; response to hypoxia; innate immune response; blood coagulation; positive regulation of DNA replication; positive regulation of cell migration. Disease: Meningioma, Familial, Susceptibility To; Dermatofibrosarcoma Protuberans; Basal Ganglia Calcification, Idiopathic, 5; Basal Ganglia Calcification, Idiopathic, 1

48-Strip-Wells

470 USD

96-Strip-Wells

675